{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:21:52Z","timestamp":1775121712118,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T00:00:00Z","timestamp":1703548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T00:00:00Z","timestamp":1703548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Ultrasonics"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Risk factors for the development of hepatocellular carcinoma (HCC) remain unclear in patients with hepatitis C virus (HCV) who achieve sustained virological response (SVR) after direct-acting antiviral (DAA) therapy. This study investigated the usefulness of the VFMAP scoring system for predicting the development of HCC in these patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study included 358 patients with HCV who achieved SVR after DAA treatment. The VFMAP system defines and scores cutoff values for virtual touch quantification (VTQ), fasting plasma glucose, sex, age, and alpha-fetoprotein values. All patients were grouped according to their VFMAP scores as follows: 0 or 1 point, low-score group; 2 or 3 points, intermediate-score group; and 4 or 5 points, high-score group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Nineteen patients developed HCC. The median follow-up duration was 3.2 (1.5\u20134.0) years. The respective cumulative incidence rates of HCC at 12, 24, and 36\u00a0months were as follows in different subgroups: all study patients, 3.0%, 4.8%, and 6.6%; low-score group, 0.96%, 0.96%, and 0.96%; intermediate-score group, 2.6%, 4.5%, and 6.8%; and high-score group, 10.0%, 15.3%, and 18.5%. The cumulative incidence rates of HCC in the high-score group were significantly higher than those in the low- and intermediate-score groups (p\u2009&lt;\u20090.001 and\u2009&lt;\u20090.05, respectively).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>VFMAP accurately predicted the development of HCC in HCV patients who achieved SVR following treatment with DAAs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10396-023-01398-5","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T06:01:49Z","timestamp":1703570509000},"page":"293-300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["VFMAP predicted hepatocellular carcinoma development in patients with chronic hepatitis C who were treated with direct-acting antiviral and achieved sustained virologic response"],"prefix":"10.1007","volume":"51","author":[{"given":"Tomomitsu","family":"Matono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Shiomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirayuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,26]]},"reference":[{"key":"1398_CR1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","unstructured":"Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161\u201376.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1398_CR2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00535-018-1532-5","volume":"54","author":"R Tateishi","year":"2019","unstructured":"Tateishi R, Uchino K, Fujiwara N, et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011\u20132015 update. J Gastroenterol. 2019;54:367\u201376.","journal-title":"J Gastroenterol"},{"key":"1398_CR3","unstructured":"European Association for the Study of the Liver, Clinical Practice Guidelines Panel: Chair, EASL Governing Board representative: Panel members. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170\u2013218."},{"key":"1398_CR4","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","volume":"153","author":"F Kanwal","year":"2017","unstructured":"Kanwal F, Kramer J, Asch SM, et al. Risk of hepatocellular cancer in HCV patients treated with directacting antiviral agents. Gastroenterology. 2017;153:996\u20131005.","journal-title":"Gastroenterology"},{"key":"1398_CR5","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","volume":"155","author":"P Nahon","year":"2018","unstructured":"Nahon P, Layese R, Bourcier V, et al. ANRS CO12 CirVir Group Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs. Gastroenterology. 2018;155:1436\u201350.","journal-title":"Gastroenterology"},{"key":"1398_CR6","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/jvh.13295","volume":"27","author":"NZ Janjua","year":"2020","unstructured":"Janjua NZ, Wong S, Darvishian M, et al. The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk. J Viral Hepat. 2020;27:781\u201393.","journal-title":"J Viral Hepat"},{"key":"1398_CR7","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/hep.25670","volume":"56","author":"DY Zhang","year":"2012","unstructured":"Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology. 2012;56:769\u201375.","journal-title":"Hepatology"},{"key":"1398_CR8","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/hep.510300624","volume":"30","author":"L Castera","year":"1999","unstructured":"Castera L, Negre I, Samii K, et al. Pain experienced during percutaneous liver biopsy. Hepatology. 1999;30:1529\u201330.","journal-title":"Hepatology."},{"key":"1398_CR9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1148\/radiol.2523081928","volume":"252","author":"M Friedrich-Rust","year":"2009","unstructured":"Friedrich-Rust M, Wunder K, Kriener S, et al. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology. 2009;252:595\u2013604.","journal-title":"Radiology"},{"key":"1398_CR10","first-page":"303","volume":"18","author":"M Lupsor","year":"2009","unstructured":"Lupsor M, Badea R, Stefanescu H, et al. Performance of a new elastographic method (ARFI technology) compared to unidimensional transient elastography in the noninvasive assessment of chronic hepatitis C. Preliminary results. J Gastrointestin Liver Dis. 2009;18:303\u201310.","journal-title":"J Gastrointestin Liver Dis"},{"key":"1398_CR11","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1478-3231.2009.02130.x","volume":"30","author":"H Takahashi","year":"2010","unstructured":"Takahashi H, Ono N, Eguchi Y, et al. Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study. Liver Int. 2010;30:538\u201345.","journal-title":"Liver Int"},{"key":"1398_CR12","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1111\/j.1365-2893.2011.01537.x","volume":"19","author":"M Friedrich-Rust","year":"2012","unstructured":"Friedrich-Rust M, Nierhoff J, Lupsor M, et al. Performance of acoustic radiation force impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat. 2012;19:e212\u20139.","journal-title":"J Viral Hepat"},{"key":"1398_CR13","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3748\/wjg.v18.i10.1077","volume":"18","author":"G Kircheis","year":"2012","unstructured":"Kircheis G, Sagir A, Vogt C, et al. Evaluation of acoustic radiation force impulse imaging for determination of liver stiffness using transient elastography as a reference. World J Gastroenterol. 2012;18:1077\u201384.","journal-title":"World J Gastroenterol"},{"key":"1398_CR14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00535-016-1228-7","volume":"52","author":"T Aoki","year":"2017","unstructured":"Aoki T, Iijima H, Tada T, et al. Prediction of development hepatocellular carcinoma using a new scoring system involving virtual touch quantification in patients with chronic liver disease. J Gastroenterol. 2017;52:104\u201312.","journal-title":"J Gastroenterol"},{"key":"1398_CR15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1872-034X.2010.00652.x","volume":"40","author":"The Japan Society of Hepatology","year":"2010","unstructured":"The Japan Society of Hepatology. Surveillance algorithm and diagnostic algorithm for hepatocellular carcinoma: Clinical Practice Guidelines for Hepatocellular Carcinoma. Hepatology Res. 2010;40:6\u20137.","journal-title":"Hepatology Res"},{"key":"1398_CR16","first-page":"518","volume":"38","author":"CT Wai","year":"2003","unstructured":"Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518\u201326.","journal-title":"Hepatology"},{"key":"1398_CR17","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jmv.24663","volume":"89","author":"M Kobayashi","year":"2017","unstructured":"Kobayashi M, Suzuki F, Fujiyama S, et al. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol. 2017;89:476\u201383.","journal-title":"J Med Virol"},{"key":"1398_CR18","first-page":"32273","volume":"S0168\u20138278","author":"GN Ioannou","year":"2017","unstructured":"Ioannou GN, Green PK, Berry K. HCV eradication induced by direct acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017;S0168\u20138278:32273.","journal-title":"J Hepatol"},{"key":"1398_CR19","doi-asserted-by":"crossref","unstructured":"Kurosaki M, Hiramatsu N, SakamotoM, et al. Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C. J Hepatol. 2012; 56: 602\u20138.","DOI":"10.1016\/j.jhep.2011.09.011"},{"key":"1398_CR20","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43:1317\u201325.","journal-title":"Hepatology"},{"key":"1398_CR21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","volume":"46","author":"A Vallet-Pichard","year":"2007","unstructured":"Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32\u20136.","journal-title":"Hepatology."},{"key":"1398_CR22","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/jgh.12915","volume":"30","author":"H Toyoda","year":"2015","unstructured":"Toyoda H, Kumada T, Tada T, et al. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2015;30:1183\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"1398_CR23","doi-asserted-by":"crossref","unstructured":"Tada T, Nishimura T, Tomomitsu M, et al. Association of liver stiffness and steatosis with hepatocellualar carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. Hepatol Res. 2120;51:860\u20139.","DOI":"10.1111\/hepr.13677"},{"key":"1398_CR24","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1872-034X.2011.00846.x","volume":"41","author":"T Akima","year":"2011","unstructured":"Akima T, Tamano M, Hiraishi H. Liver stiffness measured by transient elastography is a predictor of hepatocellular carcinoma development in viral hepatitis. Hepatol Res. 2011;41:965\u201370.","journal-title":"Hepatol Res"},{"key":"1398_CR25","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/hep.24121","volume":"53","author":"KS Jung","year":"2011","unstructured":"Jung KS, Kim SU, Ahn SH, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011;53:885\u201394.","journal-title":"Hepatology"},{"key":"1398_CR26","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/liv.12118","volume":"33","author":"HM Wang","year":"2013","unstructured":"Wang HM, Hung CH, Lu SN, et al. Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients. Liver Int. 2013;33:756\u201361.","journal-title":"Liver Int"},{"key":"1398_CR27","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/hep.22870","volume":"49","author":"R Masuzaki","year":"2009","unstructured":"Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49:1954\u201361.","journal-title":"Hepatology"},{"key":"1398_CR28","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.cgh.2013.07.034","volume":"11","author":"S Singh","year":"2013","unstructured":"Singh S, Fujii LL, Murad MH, et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1573\u201384.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1398_CR29","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/hepr.12839","volume":"47","author":"T Tada","year":"2017","unstructured":"Tada T, Kumada T, Toyoda H, et al. Post-treatment levels of alphafetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C. Hepatol Res. 2017;47:1021\u201331.","journal-title":"Hepatol Res"},{"key":"1398_CR30","volume":"96","author":"CM Huang","year":"2017","unstructured":"Huang CM, Hu TH, Chang KC, et al. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: prioritize who needs urgent direct-acting antiviral agents. Medicine (Baltimore). 2017;96: e8696.","journal-title":"Medicine (Baltimore)"},{"key":"1398_CR31","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199306243282501","volume":"328","author":"H Tsukuma","year":"1993","unstructured":"Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797\u2013801.","journal-title":"N Engl J Med"},{"key":"1398_CR32","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1038\/bjc.2013.564","volume":"109","author":"KC Chang","year":"2013","unstructured":"Chang KC, Wu YY, Hung CH, et al. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer. 2013;109:2481\u20138.","journal-title":"Br J Cancer"},{"key":"1398_CR33","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.cgh.2013.11.033","volume":"12","author":"T Oze","year":"2014","unstructured":"Oze T, Hiramatsu N, Yakushijin T, et al. Osaka Liver Forum. Post-treatment levels of a-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol. 2014;12:1186\u201395.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"1398_CR34","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00535-014-1010-7","volume":"50","author":"R Yamada","year":"2015","unstructured":"Yamada R, Hiramatsu N, Oze T, et al. Osaka Liver Forum. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection. J Gastroenterol. 2015;50:785\u201394.","journal-title":"J Gastroenterol."},{"key":"1398_CR35","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/bjc.2013.25","volume":"108","author":"WP Koh","year":"2013","unstructured":"Koh WP, Wang R, Jin A, et al. Diabetes mellitus and risk ofhepatocellular carcinoma: findings from the Singapore Chinese Health Study. Br J Cancer. 2013;108:1182\u20138.","journal-title":"Br J Cancer"}],"updated-by":[{"DOI":"10.1007\/s10396-025-01537-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:00:00Z","timestamp":1743897600000}}],"container-title":["Journal of Medical Ultrasonics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10396-023-01398-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10396-023-01398-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10396-023-01398-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T05:56:52Z","timestamp":1744005412000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10396-023-01398-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,26]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1398"],"URL":"https:\/\/doi.org\/10.1007\/s10396-023-01398-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10396-025-01537-0","asserted-by":"object"}]},"ISSN":["1346-4523","1613-2254"],"issn-type":[{"value":"1346-4523","type":"print"},{"value":"1613-2254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,26]]},"assertion":[{"value":"30 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to a retrospective open access order.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10396-025-01537-0","URL":"https:\/\/doi.org\/10.1007\/s10396-025-01537-0","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Toshifumi Tada: Lecture fees from AbbVie, Chugai Pharmaceutical, and Eisai. Takashi Nishimura and Hiroko Iijima: Lecture fees from Otsuka Pharmaceutical and research funding from Canon Medical Systems and GE Healthcare Japan. None of the other authors have potential conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval of the research protocol: The study protocol was approved by the institutional review board (#3825) of Hyogo College of Medicine.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statements"}},{"value":"Before the start of the study, written informed consent was obtained from all patients for use of their laboratory data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The institutional review board (#3825) of Hyogo College of Medicine.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Registry and the registration No. of the study"}}]}}